Am J Transplant, Volume 16, Suppl 3 Archives - Page 146 of 180 - ATC Abstracts

2016 American Transplant Congress
Validation of the Kidney Donor Risk Index (KDRI) in the Australian and New Zealand Kidney Transplant Population.
P. Clayton,^1,2,3 S. White,^1,4 S. McDonald,^1,2,3 S. Chadban.^1,4,5
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Royal Adelaide Hospital, Adelaide, SA, Australia; ²Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; ³School of Medicine, University of Adelaide, Adelaide, SA, Australia; ⁴Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁵Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Purpose: The kidney donor risk index (KDRI), developed by the United States Scientific Registry of Transplant Recipients (SRTR), was designed to quantify donor kidney quality.…
2016 American Transplant Congress
Predicting Early Cardiac Death After Kidney Transplantation.
K. Balabhadrapatruni, A. Liu, N. Sarabu, E. Sanchez, J. Augustine.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Early cardiac mortality is a devastating occurrence after transplantation. We sought to analyze risk factors and patient characteristics, including the estimated post transplant survival…
2016 American Transplant Congress
Circulating Soluble-Klotho Levels Modestly Increase After Renal Transplantation.
S.-J. Tan,¹ A. Crosthwaite,² D. Langsford,³ V. Obeysekere,⁴ F. Ierino,^2,5 M. Roberts,^5,6 S. Holt,¹ T. Hewitson,¹ K. Dwyer,^3,5,7 N. Toussaint.¹
¹Dept of Nephrology, The Royal Melbourne Hospital, Melbourne, Australia; ²Dept of Nephrology, Austin Hospital, Heidelberg, Victoria, Australia; ³Dept of Nephrology, St Vincent's Hospital, Melbourne, Australia; ⁴Dept of Endocrinology, St Vincent's Hospital, Melbourne, Australia; ⁵Victorian Kidney Transplantation Collaborative, Melbourne, Australia; ⁶Dept of Renal Medicine, Eastern Health, Box Hill, Australia; ⁷School of Medicine, Deakin University, Geelong, Australia.
Background: Klotho, a co-receptor for FGF23, is predominantly expressed in kidney and reported to have anti-oxidant and anti-fibrotic properties. Soluble-Klotho (sKl), the cleaved circulating protein,…
2016 American Transplant Congress
Pre-Mortem Cannulation and NECMO Preservation for DCD Liver Transplantation.
P. Ruiz,¹ M. Gastaca,¹ A. Valdivieso,¹ A. Ventoso,¹ I. Palomares,¹ M. Prieto,¹ J. Bustamante,² P. Salvador,² J. Ortiz de Urbina.¹
¹Liver Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Vizcaya, Spain; ²Hepatology and Liver Transplant Unit, Cruces University Hospital, Bilbao, Vizcaya, Spain.
Introduction: Herein, we present the short-term results of a controlled DCD liver transplantation program with pre-mortem cannulation and normothermic extracorporeal membrane oxygenation (NECMO) preservation.Material and…
2016 American Transplant Congress
Increased Utilization of High Risk Deceased Donors with Share 35 Does Not Affect Outcomes in Liver Transplantation.
M. Boktour, A. Saharia, D. Victor, S. Gordon-Burroughs, C. Mobley, R. McFadden, V. Ankoma-Sey, J. Galati, A. Gaber, H. Monsour, R. Ghobrial.
Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX.
Background: Demand for livers from deceased donors exceeds supply after Share 35 in June 2013. This leads liver transplant centers to consider high risk deceased…
2016 American Transplant Congress
Outcomes in Lung Transplant Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) in the Perioperative Period.
A. Habertheuer, M. Williams, S. Miller, E. Cantu, C. Bermudez, P. Vallabhajosyula.
Cardiovascular Surger, Hospital of the University of Pennsylvania, Philadelphia, PA.
Objective As ECMO therapy is increasingly used to bridge high-risk patients with end-stage respiratory failure to lung transplantation, outcomes of this strategy employed in the…
2016 American Transplant Congress
C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains.
C. Blosser,¹ Y. Zhang,² T. Dhawale,³ C. Johnson,¹ P. Hendrie,³ R. Smith.²
¹Medicine, University of Washington, Seattle, WA; ²Medicine & Surgery, University of Iowa, Iowa City, IA; ³Medicine, Seattle Cancer Care Alliance, Seattle, WA.
Background: Monoclonal gammopathy of renal significance (MGRS) implies a causal relationship between clonal B cell proliferation and renal disease and is associated with high morbidity…
2016 American Transplant Congress
A Novel Study to Determine the Association of Pre-Transplant Donor Specific Antibody and AT₁R Antibody with Kidney Transplant Outcomes Prior to Adoption of Solid Phase Antibody Assays.
R. Redfield, B. Astor, B. Jung-Hynes, D. Mandelbrot, D. Kaufman, A. Djamali, T. Ellis.
University of Wisconsin, Madison.
Background: Studies assessing the risk of pre-transplant antibodies are generally restricted to low levels of donor specific antibody (DSA). Here we analyze pre-transplant HLA DSA,…
2016 American Transplant Congress
The Coefficient of Variability of Tacrolimus Levels Can Predict Antibody-Mediated Rejection After Renal Transplantation.
P. Ruiz-Esteban,¹ M. Gonzalez-Molina,¹ A. Caballero,² E. Palma,¹ D. Burgos,¹ M. Cabello,¹ J. Alonso-Titos,¹ A. Duarte,¹ D. Hernandez.¹
¹Nephrology, Regional Universitary Hospital, IBIMA, University of Malaga, Malaga, Spain; ²Immunology, Regional University Hospital, IBIMA, University of Malaga, Malaga, Spain.
Introduction. Antibody-mediated rejection (ABMR) is the major cause of allograft failure. We studied whether the coefficient of variability (CV) of blood levels of tacrolimus can…
2016 American Transplant Congress
Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.
M. McAdams-DeMarco, Q. Huang, X. Luo, B. Orandi, S. Dorry.
Johns Hopkins, Baltimore.
Background: Clinical trials of induction agents typically exclude older recipients, so our practice in older recipients is extrapolated from this. Older adults are different, so…